Trial · NCT03948685
Registered outcomes27
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 27
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The Maximum NT-proBNP value change after Drug(Carvedilol SR or Placebo) administration. | Baseline | The maximum NT-proBNP value change at baseline. |
| Primary | The Maximum NT-proBNP value change after Drug(Carvedilol SR or Placebo) administration. | 8 weeks | The maximum NT-proBNP value change from baseline to 8 weeks. |
| Primary | The Maximum NT-proBNP value change after Drug(Carvedilol SR or Placebo) administration. | 24 weeks | The maximum NT-proBNP value change from baseline to End of trial(24weeks). |
| Secondary | The changes of maximum surrogate markers values(hsTn, hsCRP, sST2, Galectine-3, IGFBP7, Neprilysin, D-dimer, MMP-2, Cystatin C, NAG, NGAL, KIM-1, BUN, Creatinine, Chloride, Na, K, PICP and spondin-1) after Drug(Carvedilol SR or Placebo) administration. | Baseline | the change of surrogate markers(hsTn, hsCRP etc) at baseline. |
| Secondary | The changes of maximum surrogate markers values(hsTn, hsCRP, sST2, Galectine-3, IGFBP7, Neprilysin, D-dimer, MMP-2, Cystatin C, NAG, NGAL, KIM-1, BUN, Creatinine, Chloride, Na, K, PICP and spondin-1) after Drug(Carvedilol SR or Placebo) administration. | 8 weeks | the change of surrogate markers(hsTn, hsCRP etc) after 8 weeks. |
| Secondary | The changes of maximum surrogate markers values(hsTn, hsCRP, sST2, Galectine-3, IGFBP7, Neprilysin, D-dimer, MMP-2, Cystatin C, NAG, NGAL, KIM-1, BUN, Creatinine, Chloride, Na, K, PICP and spondin-1) after Drug(Carvedilol SR or Placebo) administration. | 16 weeks | the change of surrogate markers(hsTn, hsCRP etc) after 16 weeks. |
| Secondary | The changes of maximum surrogate markers values(hsTn, hsCRP, sST2, Galectine-3, IGFBP7, Neprilysin, D-dimer, MMP-2, Cystatin C, NAG, NGAL, KIM-1, BUN, Creatinine, Chloride, Na, K, PICP and spondin-1) after Drug(Carvedilol SR or Placebo) administration. | 24 weeks | the change of surrogate markers(hsTn, hsCRP etc) from baseline to end of trial(24 weeks) |
| Secondary | The change in degree of dyspnea using VAS questionnaire | Baseline | the change of dyspnea at baseline. |
| Secondary | The change in degree of dyspnea using VAS questionnaire | 8 weeks | the change of dyspnea after 8 weeks. |
| Secondary | The change in degree of dyspnea using VAS questionnaire | 16 weeks | the change of dyspnea after 16 weeks. |
| Secondary | The change in degree of dyspnea using VAS questionnaire | 24 weeks | the change of dyspnea from baseline to end of trial(24 weeks) |
| Secondary | the change of body weight | Baseline | the change of body weight at baseline. |
| Secondary | the change of body weight | 8 weeks | the change of body weight after 8 weeks. |
| Secondary | the change of body weight | 16 weeks | the change of body weight after 16 weeks. |
| Secondary | the change of body weight | 24 weeks | the change of body weight from baseline to end of trial(24 weeks) |
| Secondary | the frequency of symptomatic hypotension, symptomatic bradycardia and AV block above 2nd degree | Baseline | the frequency of symptomatic hypotension, symptomatic bradycardia and AV block above 2nd degree during the tiral |
| Secondary | the frequency of symptomatic hypotension, symptomatic bradycardia and AV block above 2nd degree | 8 weeks | the frequency of symptomatic hypotension, symptomatic bradycardia and AV block above 2nd degree during the tiral |
| Secondary | the frequency of symptomatic hypotension, symptomatic bradycardia and AV block above 2nd degree | 16 weeks | the frequency of symptomatic hypotension, symptomatic bradycardia and AV block above 2nd degree during the tiral |
| Secondary | the frequency of symptomatic hypotension, symptomatic bradycardia and AV block above 2nd degree | 24 weeks | the frequency of symptomatic hypotension, symptomatic bradycardia and AV block above 2nd degree during the tiral |
| Secondary | the frequency of hypo/hyperkalemia and worsening kidney function | Baseline | the frequency of hypo/hyperkalemia and worsening kidney function during the trial |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03948685/registered